ArticleBMC biotechnology2025
Lactococcus lactis I7 isolated from traditional Italian cheese making: a biotechnological integrated platform.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Biotechnological Platform Based on the Newly Isolated Streptococcus thermophilus D4 to Obtain Viable Biomass and Exopolysaccharides for Enterocytes Wound Healing.Biotechnology and bioengineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is growing interest in newly isolated lactic acid bacteria from traditional sources. In this study, a Lactococcus lactis strain identified and isolated from natural whey starter cultures of cow milk for the production of artisanal cheeses was cultivated in optimized vegan grade medium to assess its growing ability and metabolic fingerprint. In fact, traditionally fermented dairy products are considered nutritionally complete and possibly functional to human health with a number of benefits not only to the gastro-intestinal tract but also in a systemic manner.
resultsIn fed batch experiments, we achieved 14 g/L dry cell weight and 1.9∙10
conclusionThis paper focused its attention on optimization of fermentation conditions (in particular a vegan grade media using Design of Experiment approach) using fed-batch and microfiltration processes increasing the production of biomass and bioactive molecules, with respect to the batch processes. At the end of the fed-batch fermentation, a downstream process based on membranes was performed in order to obtain bioactive molecules that proved antimicrobial activity against intestinal/food spoilage pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.